Plasma exchange for rheumatoid arthritis.

Area of Science:

• Rheumatology
• Immunology
• Medical Technology

Background:

• Rheumatoid arthritis (RA) is a prevalent inflammatory joint disease with incompletely understood pathophysiology.
• Circulating immune complexes and rheumatoid factors have historically guided RA treatment strategies.
• The evolution of disease-modifying anti-rheumatic drugs (DMARDs) has impacted the role of extracorporeal therapies in RA management.

Purpose of the Study:

• To evaluate the historical and current role of plasma exchange (PE) and related apheresis techniques in managing rheumatoid arthritis.
• To assess the efficacy of immunoadsorption compared to plasma exchange in refractory RA cases.
• To contextualize the use of these therapies in light of advancements in biologic treatments for RA.

Main Methods:

• Review of plasma exchange (PE) and leukapheresis outcomes in severe and resistant rheumatoid arthritis (RA) patients.
• Analysis of immunoadsorption efficacy, specifically using Staphylococcus aureus protein A columns, in refractory RA.
• Comparison of apheresis techniques with the advent and impact of biologic therapies in RA treatment.

Main Results:

• Plasma exchange and leukapheresis yielded disappointing results in severe, resistant RA.
• Immunoadsorption demonstrated some positive responses in refractory RA patients.
• The emergence of effective biologic agents has significantly reduced the indications for PE and immunoadsorption in RA.

Conclusions:

• Extracorporeal therapies like plasma exchange and leukapheresis have limited efficacy in severe rheumatoid arthritis.
• Immunoadsorption shows potential but its use is now restricted due to the success of biologic therapies.
• Current indications for apheresis in RA are limited to rare cases of severe, refractory disease unresponsive to other treatments.